Status:
COMPLETED
A Study of rhBMP-2/CPM in Closed Fractures of the Humerus
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Fractures
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objective of this study is to assess whether fracture union is accelerated in subjects with humeral fractures (proximal,diaphyseal) treated with conservative therapy (standard of care) and...
Eligibility Criteria
Inclusion
- Skeletally mature subjects age 18 years or older.
- Subjects with either a closed proximal humeral fracture or a diaphyseal humeral fracture.
- Treatment plan that includes only conservative (nonoperative) therapy within 48 hours following injury.
Exclusion
- Shoulder dislocation at the time of injury.
- Planned procedure(s) at that would stimulate fracture union at the time of application of the initial immobilization device.
- Fractures located in the distal third of humerus.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
139 Patients enrolled
Trial Details
Trial ID
NCT00384852
Start Date
January 1 2007
End Date
February 1 2010
Last Update
February 28 2013
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
Little Rock, Arkansas, United States, 72205
2
Aurora, Colorado, United States, 80012
3
Denver, Colorado, United States, 80204
4
Clearwater, Florida, United States, 33756